West Pharmaceutical Services, Inc. WST

370.44 (3.16) (0.85%) as of 25 Sep
Market cap
$26.3B
P/E
47.1×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

West Pharmaceutical Services, Inc. (WST) Free cash flow margin

West Pharmaceutical Services, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 13.1%, down 2.1 percentage points from fiscal 2025 (15.3%). Over the past ten years it has ranged from 3.26% (fiscal 2016) to 15.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Instruments & Supplies industry median of 1.61% and above the Healthcare sector median of 0.00%.

Free cash flow margin, annual

Annual

Period Free cash flow margin Change (points)
FY2025 15.3% 5.70
FY2024 9.55% (4.50)
FY2023 14.1% (1.17)
FY2022 15.2% 3.54
FY2021 11.7% (2.21)
FY2020 13.9% 0.80
FY2019 13.1% 2.38
FY2018 10.7% 2.42
FY2017 8.29% 5.03
FY2016 3.26% (2.51)

Against its own ten years

Low 3.26% High 15.3%
Ten-year median 11.7%
Current reading's percentile 100

Free cash flow margin against peers

Company Free cash flow margin
RMD ResMed Inc. compare 28.8%
COO The Cooper Companies, Inc. compare 16.0%
ALC Alcon compare 14.7%
BDX Becton, Dickinson and Company compare 14.3%
RGEN Repligen Corporation compare 14.1%
WST West Pharmaceutical Services, Inc. 13.1%
MDLN Medline Inc. compare 7.75%
BAX Baxter International Inc. compare 7.11%
SOLV Solventum Corporation compare −1.42%
Medical Instruments & Supplies industry median 1.61%
Healthcare sector median 0.00%
Market median 0.00%

What Free cash flow margin is

Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.

(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue

The full definition of Free cash flow margin →

More on WST